Trials / Completed
CompletedNCT03970122
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Goldfinch Bio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study will comprise primarily a single-ascending dose (SAD) escalation component.
Detailed description
Double-blind, randomized, placebo-controlled, single-dose, sequential-group design in up to 7 cohorts of healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GFB-887 | IMP |
| DRUG | Placebo | Matching |
Timeline
- Start date
- 2019-05-29
- Primary completion
- 2020-03-04
- Completion
- 2020-04-04
- First posted
- 2019-05-31
- Last updated
- 2020-06-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03970122. Inclusion in this directory is not an endorsement.